Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
APOB product is the main apolipoprotein of chylomicrons and low density lipoproteins. Additionally we are shipping APOB Kits (127) and APOB Proteins (26) and many more products for this protein.
Showing 10 out of 354 products:
Human Polyclonal APOB Primary Antibody for EIA, WB - ABIN112988
Herscovitz, Derksen, Walsh, McKnight, Gantz, Hadzopoulou-Cladaras, Zannis, Curry, Small: The N-terminal 17% of apoB binds tightly and irreversibly to emulsions modeling nascent very low density lipoproteins. in Journal of lipid research 2001
Show all 6 references for ABIN112988
Human Polyclonal APOB Primary Antibody for EIA, IP - ABIN318832
Olofsson, Borèn: Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. in Journal of internal medicine 2005
Show all 2 references for ABIN318832
Human Monoclonal APOB Primary Antibody for ICC, FACS - ABIN968961
Peterson, Mack, Hall, Alsup, Alexander, Sully, Sawires, Cheung, Otto, Gresham: Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. in Cell host & microbe 2008
Show all 2 references for ABIN968961
Human Monoclonal APOB Primary Antibody for EIA, IHC (fro) - ABIN1105418
Valentinova, Gu, Yang, Yanushevskaya, Antonov, Guyton, Smith, Gotto, Yang: Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. in Biological chemistry Hoppe-Seyler 1995
Human Monoclonal APOB Primary Antibody for EIA, IF - ABIN1105414
Benn: Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. in Atherosclerosis 2009
Human Polyclonal APOB Primary Antibody for IF (p), IHC (p) - ABIN872950
Choi, de Poot, Lee, Kim, Han, Kim, Finley, Lee: Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. in Nature communications 2016
Human Polyclonal APOB Primary Antibody for ELISA, WB - ABIN449695
Benn, Nordestgaard, Jensen, Tybjaerg-Hansen: Polymorphisms in apolipoprotein B and risk of ischemic stroke. in The Journal of clinical endocrinology and metabolism 2007
Human Polyclonal APOB Primary Antibody for IHC, WB - ABIN2776957
Kamdem, Hamilton, Cheng, Liu, Yang, Johnson, Pui, Relling: Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. in Pharmacogenetics and genomics 2008
Higher level of some risk factors like PAB values, apoB/A1 ratio concentration, and lipid profiles is able to involve in the prognostic pathological consequences in patients with beta-thalassemia major. Even so, they contribute toward the gradual development of CVD.
Multiple novel LDLR (show LDLR Antibodies) and ApoB mutations have been identified in a-United Kingdom-based cohort with familial hypercholesterolemia.
Data suggest that LDL-C/apoB ratio (ratio of plasma level of total cholesterol to plasma level of apolipoprotein B) is an important biomarker in overall evaluation of atherogenicity in obese, overweight, and normal-weight men; this study of qualitative changes in lipid/lipoprotein profile for early diagnosis of dyslipidemias leading to atherosclerosis was conducted in Russia.
Mutations in APOB is associated with hypobetalipoproteinemia.
LDLR (show LDLR Antibodies) A(+)A(+) genotype, ApoB X(+) allele and ApoE (show APOE Antibodies) E4 allele increased the risk of premature coronary artery disease by 1.8, 2.1 and 12.1 respectively.
C7673T polymorphism in apoB gene is significantly associated with increased ischemic stroke risk in the Chinese population.
Apo (show C9orf3 Antibodies)-B correlation with both LDL-C and non-HDL (show HSD11B1 Antibodies)-C is reduced in individuals with high TG levels and in particular for those with diabetes or MetS (show ETV3 Antibodies).
Report increased intestinal cholesterol absorption and elevated serum cholesterol in families with primary hypercholesterolemia without mutations in APOB.
associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population
Data indicate that serum apolipoproteins ApoB, ApoA-1 (show APOA1 Antibodies) and ApoB/A-1 ratio levels are independently associated with coronary heart disease (CHD (show CHDH Antibodies)) risk in Korean men.
A transposable element insertion in APOB causes cholesterol deficiency in Holstein cattle
Nonesterified fatty acids significantly inhibit the expression of ApoB100, ApoE (show APOE Antibodies), MTP (show MTTP Antibodies), and LDLR (show LDLR Antibodies), thereby decreasing the synthesis and assembly of VLDL and inducing TG accumulation in bovine hepatocytes.
after calving the apolipoprotein B(100) mRNA synthesis was lower, whereas microsomal triglyceride transfer protein (MTP (show MTTP Antibodies)) and apolipoprotein E (show APOE Antibodies) messenger RNA abundance were higher in the liver.
The effect of hypercholesterolemia induced immune response and inflammation on progression of atherosclerosis in ApoB(tm25gy) LDLr (show LDLR Antibodies)(tm1Her) mice, expressing only ApoB100 and deficient in the low density lipoprotein receptor (show LDLR Antibodies).
ApoB-containing lipoproteins contribute to augmentation of AngII-induced abdominal aortic aneurysms in male mice.
Immunization with human apolipoprotein B100 (ApoB) resulted in four-fold increased accumulation of effector T cells in ApoB-containing matrigel
PCSK9 (show PCSK9 Antibodies) markedly increases intestinal triglyceride-rich apoB production through mechanisms mediated in part by transcriptional effects on apoB.
Mice that produce apoB100 in the RPE (show RPE Antibodies) and liver secrete lipoproteins into Bruch's membrane, but not to the extent that distinct features of AMD (show AMD1 Antibodies) develop
The aim of this study was to characterize the ocular morphology of low-density lipoprotein receptor-deficient apolipoprotein B-100-only mice, with IGF-II overexpression.
Our data establish the role of APOB gene in severe gut (show GUSB Antibodies) dysmotility.
Cardiac lipotoxicity may originate from direct inhibition of myocardial ApoB lipoprotein and subsequent decreased lipid export, caused by supraphysiological levels of catecholamines.
ApoB-100 transgenic animals present i) elevated serum and cerebral levels of triglycerides and ApoB-100, ii) increased cerebral tau phosphorylation at phosphosites Ser (show SIGLEC1 Antibodies)(199), Ser (show SIGLEC1 Antibodies)(199/202), Ser (show SIGLEC1 Antibodies)(396) and Ser (show SIGLEC1 Antibodies)(404).
model in which increased hepatic sortilin (show SORT1 Antibodies) binds intracellular APOB-containing particles in the Golgi apparatus as well as extracellular LDL at the plasma membrane and traffics them to the lysosome for degradation
found association between genotypes for LDLR (show LDLR Antibodies) and APOB polymorphisms and serum lipid levels, but none of them seem to be the causal mutation but probably represent closely linked polymorphisms
This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.
, apolipoprotein B (including Ag(x) antigen)
, apolipoprotein B-100
, apolipoprotein B48
, mutant Apo B 100
, apolipoprotein B PI
, apolipoprotein B-48
, apolipoprotein B